Cohance Lifesciences' API unit 1 completes USFDA inspection
(11 Sep 2025)

Back
Cohance Lifesciences announced that the United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at its API manufacturing facility (API Unit 1) located at Jaggaiahpet, Andhra Pradesh.

The inspection was conducted from 08 September 2025 to 11 September 2025 and concluded with zero Form 483 observations.

Copyright © 2024 Arihant Capital Markets Ltd. All rights Reserved.

Designed,Developed and Content powered by CMOTS Infotech (ISO 9001:2015 certified)

x
  • QR-CodeNew